

Table 4 Comparison of reports of adverse events following immunization (AEFI) by type of vaccine in developed counties and in the present study in Oman

Vaccine	Oman	USA	Australia	Oman	Canada
	1996-2005 ^a	1991-2001 ^b	2000-2002 ^c	1996-2005 ^a	1993-1997 ^d
	AEFI per 100 000 doses	AEFI per 100 000 doses	AEFI per 100 000 doses	No. of AEFI reports received	No. of AEFI reports received
BCG	69.7	-	-	326	170
DTP	15.3	26.2	42.3	296	4 310
DTP-HBV	-	-	25.2	-	-
Hib	2.3	18.1	23.1	4	10 487
Hib-HBV	-	12.9	12.1	-	-
Measles	2.9	12.0	-	14	1 244
MMR	3.6	16.3	26.6	17	2 188
HBV	1.5	11.8	10.4	23	1 961
Penta	21.7	-	-	71	-

Sources: ^aCurrent study; ^b[7]; ^c[8]; ^d[11].

USA = United States of America; BCG = bacille Calmette-Guérin; DTP = diphtheria-tetanus-pertussis; HBV = hepatitis B virus; Hib = Haemophilus influenzae type B; MMR = measles-mumps-rubella; penta = DTP-Hib-HBV; - = data not available.